Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen and Wyeth Alzheimer’s drug produces results

Amgen and Wyeth Alzheimer’s drug produces results

21st July 2008

A drug created for patients suffering from Alzheimer’s has produced “dramatic improvements”, according to Reuters.

Enbrel (etanercept) is a rheumatoid arthritis drug which has been trialled in a small study of 12 patients.

Many reported greatly improved language recall soon after the drug was administered.

The drug was created by Dr Edward Tobinick, director of the Institute for Neurological Research, a private medical group.

According to Reuters, Dr Tobinick charges between $10,000 (5,006 pounds) and $40,000 for treatment.

He believes the drug works by blocking an excess of tumour necrosis TNF-alpha which may affect communication skills.

The Alzheimer’s Association said: “People with Alzheimer’s and their families may place undue value on this new finding based on the dramatic language used in its description and the apparent immediate effect.”

It called for further independent research into Enbrel.

None of the 12 patients in Dr Tobinick’s study were given a placebo and all knew they were taking a drug.

The Alzheimer’s Association said that around five million people living in the US have the disease and it is the sixth most common cause of death in the country.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.